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Abstract
Background: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring of
multiple sclerosis (MS). In clinical trials, MRI has been found to detect treatment effects with greater sensitivity than
clinical measures; however, clinical and MRI outcomes tend to correlate poorly.
Methods: In this observational study, patients (n = 550; 18-50 years; relapsing-remitting MS [Expanded Disability
Status Scale score ≤4.0]) receiving interferon (IFN) b-1a therapy (44 or 22 µg subcutaneously [sc] three times
weekly [tiw]) underwent standardized MRI, neuropsychological and quality-of-life (QoL) assessments over 3 years. In
this post hoc analysis, MRI outcomes and correlations between MRI parameters and clinical and functional
outcomes were analysed.
Results: MRI data over 3 years were available for 164 patients. T2 lesion and T1 gadolinium-enhancing (Gd+) lesion
volumes, but not black hole (BH) volumes, decreased significantly from baseline to Year 3 (P < 0.0001). Percentage
decreases (baseline to Year 3) were greater with the 44 μg dose than with the 22 μg dose for T2 lesion volume
(-10.2% vs -4.5%, P = 0.025) and T1 BH volumes (-7.8% vs +10.3%, P = 0.002). A decrease in T2 lesion volume over
3 years predicted stable QoL over the same time period. Treatment with IFN b-1a, 44 μg sc tiw, predicted an
absence of cognitive impairment at Year 3.
Conclusion: Subcutaneous IFN b-1a significantly decreased MRI measures of disease, with a significant benefit shown
for the 44 µg over the 22 µg dose; higher-dose treatment also predicted better cognitive outcomes over 3 years.
Background
Magnetic resonance imaging (MRI) can provide valuable
information on the type, extent and location of pathologi-
cal lesions in patients with multiple sclerosis (MS).
Increasingly, MRI is routinely used in the diagnosis and
monitoring of MS, being integral to the McDonald criteria
[1]. In addition, MRI measures have been widely used as
secondary [2-5] and, more recently, primary [6] outcome
measures in large clinical trials of new MS therapies. In
the pivotal PRISMS (Prevention of Relapses and disability
by Interferon-b-1a Subcutaneously in Multiple Sclerosis)
study, subcutaneous (sc) interferon (IFN) b-1a, 44 or 22
µg three times weekly (tiw), significantly reduced relapse-
related outcomes in patients with relapsing-remitting MS
(RRMS) [7]. Treatment with sc IFN b-1a was also found
to significantly reduce MRI measures of disease at 2 years
compared with placebo [7]. Significant effects included
reductions in T2 burden of disease (BOD; P < 0.0001 for
both doses vs placebo), the number of T2 active lesions
(P < 0.0001 for both doses vs placebo), and the number of
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combined unique active (CUA) lesions (P < 0.0001 for
both doses vs placebo) [4,7]. Furthermore, a significant
benefit of the higher over the lower dose was seen for
some measures, including the number of active T2 lesions,
as reported for clinical outcomes [7]. Beneficial effects of
treatment with sc IFN b-1a on MRI measures of disease
were also detected in this patient cohort after 7 to 8 years
of follow-up, again with evidence of a dose effect [8].
In addition to long-term monitoring of treatment-
related outcomes, MRI, unlike clinical measures, can
detect early treatment effects. Recently, rapid benefits of
IFN b-1a in RRMS were detected using MRI. Notably,
patients receiving active treatment had 69% fewer CUA
lesions than those receiving placebo after 16 weeks of
treatment (P < 0.001) [6]. A post hoc analysis revealed a
significant effect on the number of CUA lesions as early
as week 4 after starting treatment [6]. The effect of IFN
b-1a on ‘newer’ MRI measures including T1 black holes
(BH), which indicate areas of axonal loss and permanent
tissue damage, is less clear.
Although MRI provides valuable insights into MS,
conventional MRI measures have tended to correlate
poorly with clinical outcomes [9,10]. This discrepancy is
believed to arise for several reasons, such as the pre-
sence of clinically silent MRI lesions, functional plasti-
city, and the failure of neurological measures such as
the Expanded Disability Status Scale (EDSS) to capture
psychosocial symptoms and cognitive impairment.
Cognitive impairment is experienced by up to 65% of
patients with MS [11] and can result in considerable dis-
ability, loss of social functioning, and reduced quality of
life (QoL) [12,13]. Previous studies in MS have reported
associations between the development of brain MRI
lesions and cognitive impairment [14,15]. In the prospec-
tive, multicentre, observational COGIMUS (COGnitive
Impairment in MUltiple Sclerosis) study of mildly disabled
patients with RRMS, we reported that T2 hyperintense
and T1 hypointense lesion volumes at baseline were signif-
icantly higher in patients with cognitive impairment than
in those without [16]. Indeed, T2 lesion volume was also
found to be a significant predictor of cognitive impairment
at baseline [16]. In addition, weak associations were found
between cognitive performance test results and specific
MRI measures in this population [16].
In COGIMUS, ~20% of patients who received sc IFN
b-1a were found to have cognitive impairment at base-
line (22 µg sc tiw: 24.2%, 44 µg sc tiw: 18.6% [P =
0.145]) despite having only a low level of physical dis-
ability (mean [standard deviation; SD] EDSS score was
1.8 [1.0]) [16,17]. Further, 3-year results from COGI-
MUS suggested that treatment with IFN b-1a, 44 or 22
µg sc tiw, may have a dose-dependent protective effect
on cognition in this mildly disabled patient population
[17,18]. Here we report the results of a post hoc analysis
of the longitudinal effects of treatment on MRI mea-
sures of disease over 3 years in the COGIMUS study.
Associations between MRI measures and cognitive and
patient-reported outcomes were assessed to explore
whether beneficial treatment effects on MS lesions were
related to those on cognition.
Methods
Patients and study design
COGIMUS was a prospective, multicentre, observational,
3-year study to assess the effects of IFN-b treatment on
cognition in a large cohort of Italian patients with RRMS.
The study was performed with respect to the Declaration
of Helsinki and according to good clinical practice
recommendations (Ethics Committee registration num-
ber 78 of the Clinical Experiments Register; 2002, DOI78
Prot. 43 02/08/2002). Full details of the study design have
been described elsewhere [16,17]. Briefly, patients aged
18-50 years, with a diagnosis of RRMS (McDonald cri-
teria) [1] and an EDSS score of ≤4.0, and who were naïve
to disease-modifying drugs (DMDs), were eligible for
inclusion in the study. Patients were assigned to one of
three IFN-b treatment regimens: sc IFN b-1a (44 or 22
μg tiw), intramuscular (im) IFN b-1a (30 μg once weekly),
or sc IFN b-1b (250 μg every other day); the choice of
treatment was made entirely at the discretion of the
treating physician following discussion with the indivi-
dual patient. All patients gave written informed consent.
Most patients enrolled into the study (459/550; 83.5%)
were assigned sc IFN b-1a treatment. As reported else-
where [17], 64 patients (11.6%) were assigned im IFN b-
1a and 27 patients (4.9%) were assigned sc IFN b-1b, of
whom only 13 and 19 patients, respectively, were avail-
able for follow-up at 3 years; due to the low patient num-
bers and high drop-out rates, the current analyses were
restricted to the cohort of patients who received sc IFN
b-1a. MRI outcomes were compared in patients who
received sc IFN b-1a, 44 or 22 µg sc tiw; additional post
hoc analyses were performed on pooled data from these
two patient groups.
MRI assessments
Standardized MRI scans were performed using a 1.5 Tesla
scanner to determine T1 gadolinium-enhancing (Gd+)
lesions, and T1 hypointense and T2 hyperintense lesion
volumes. Brain MRI scans were performed annually with
strict repositioning criteria using standard landmarks. All
centres followed a standardized MRI protocol [16]. Briefly,
MRI scans were obtained on a high-field magnet. Forty-
eight interleaved 3-mm slices were acquired for each
sequence, on axial plane; a 250 field of view (FOV) and
256 × 256 matrix were obtained. Specifications included
pre-contrast T1: TR 500-650, TE 10-20, one excitation,
6-minute acquisition; post-contrast T1: TR 500-650, TE
Bastianello et al. BMC Neurology 2011, 11:125
http://www.biomedcentral.com/1471-2377/11/125
Page 2 of 9
10-20, one excitation, 6-minute acquisition; dual-echo
sequence: TR 2000-3200, TE 20-50 and TE 80-120, two
excitations, turbo factor 4-6, 5-minute acquisition; T2
Fast-FLAIR: TR 6000-9999, TE 150-200, TI 2000-2500,
one excitation, turbo factor 11-18, 6-8 minutes acquisition.
Scans were analysed centrally by expert observers who
were blinded to clinical data.
Neuropsychological, QoL and psychosocial assessments
Cognitive performance was assessed at baseline and
annually up to Year 3. The results of neuropsychological
assessments have been reported in detail elsewhere [16].
Briefly, cognitive performance was assessed using Rao’s
Brief Repeatable Battery and the Stroop Test. Impaired
performance was defined as a test result 1 SD below Ita-
lian mean normative values [19]; impaired performance on
≥3 tests indicated cognitive impairment [16]. As the num-
ber of patients with impaired performance on ≥3 tests and
full MRI data was too low for statistical analysis, for the
purposes of this post hoc study we performed additional
analyses to assess the association between outcomes and
cognition in which cognitive impairment was defined as
impaired performance on ≥2 tests.
Intelligence quotient (IQ) was determined using the
Brief Intelligence Test [20]. Fatigue (Fatigue Impact
Scale; FIS) [21], depressive symptoms (Hamilton Depres-
sion Rating Scale; HDRS [22], social functioning (Envir-
onmental Status Scale; ESS) [23] and QoL (Multiple
Sclerosis Quality of Life-54 [MSQoL-54] questionnaire)
were assessed at baseline and annually thereafter.
Statistical analyses
Quantitative variables were expressed as means (SD)
and medians (Q1, Q3). Discrete and continuous vari-
ables were analysed using non-parametric tests: the
Mann-Whitney test for between-group comparisons, the
Wilcoxon signed rank test for repeated comparisons,
and Pearson’s chi-square test or Fisher’s exact test to
compare categorized proportions of patients.
Multivariate logistic regression was used to test associa-
tions between MRI variables and clinical and QoL out-
comes. Only variables that were significant (P ≤ 0.05) in
univariate models were included in the multivariate
model. A clinically relevant change in QoL score was
defined as a change of 0.5 - SD or more from baseline to
Year 3 (0.5 + SD for the ESS and its subscales) [24]. No
adjustments were made for multiple comparisons and
there was no imputation of missing data. All statistical
analyses were performed using SAS 8.2 and STATA 8.2.
Results
Patients and data availability
Baseline MRI data were available for 327/459 (71.2%)
patients receiving sc IFN b-1a, for whom MRI data over
3 years of follow-up were available for 164 (35.7%),
although all parameters were not available at every time
point for all patients. Data were missing for 163 patients
either because these patients were lost to follow-up or
because the scans were unreadable for technical reasons
(e.g. software upgrade, optical disc damage).
Among the 164 patients who had 3-year follow-up MRI
data, mean (SD) age was 33 (8) years and 102 (62.2%)
were women; mean (SD) disease duration was 5 (5) years
and the mean (SD) baseline EDSS score was 2 (0.8). Base-
line characteristics were compared in patients with and
without MRI follow-up data. No significant differences
between these two groups were observed in sex ratio,
age, education, QoL, IQ scores (verbal, performance or
total IQ) or sc IFN b-1a dose. Significant differences
were seen between patients with and without MRI fol-
low-up for: impaired performance on ≥3 tests (12.1% vs
26.5%; P = 0.0003); disease duration (mean [SD]: 4.8 [4.9]
vs 3.2 [4.1] years; P < 0.0001); EDSS score (mean [SD]:
2.0 [0.8] vs 1.7 [1.0]; P = 0.0037) and HDRS score (mean
[SD]: 8.0 [5.2] vs 6.1 [4.6]; P = 0.0002).
Effect of sc IFN b-1a on MRI outcomes (pooled data)
At Year 3, both T2 lesion and T1 Gd+ lesion volumes
were significantly lower than at baseline (Table 1). The
mean (SD) absolute decrease in T2 lesion volume was
644.2 (3072.1) mm3 and the mean percentage change was
-7.6% (P < 0.0001 vs baseline; both measures). T1 Gd+
lesion volume decreased by 48.2 (269.3) mm3 (P = 0.0034
vs baseline), and mean percentage change from baseline
was -60.5% (P < 0.0001). T1 black hole (BH) volume did
not decrease significantly from baseline to Year 3.
The proportion of patients who were free from new
T2 lesions, new T1 Gd+ lesions and new BH at all time
points from baseline to Year 3 were: 51.2% (84/164),
83.8% (134/160) and 68.5% (111/162), respectively.
When only scans from baseline and Year 3 were consid-
ered, 79.9% (131/164) of patients, 93.1% (149/160) and
88.3% (144/163) of patients were free from new T2
lesions, new T1 Gd+ lesions and new BH, respectively.
Comparison of effects of sc IFN b-1a, 44 and 22 µg, on
MRI outcomes
No significant differences between the two dosage groups
were seen in T2, T1 Gd+ or BH lesion volumes at any
timepoint. The number of new T2, T1 Gd+ and BH
lesions did not differ between dosage groups at any time
point (Year 1, 2 or 3) nor was there any significant differ-
ence in the cumulative number of new lesions over the 3
years of follow-up (data not shown).
Treatment with IFN b-1a, 44 µg sc tiw, was associated
with a significantly greater percentage decrease in T2
lesion volume from baseline to Year 3 than that seen
with the 22 µg sc tiw dosage (P = 0.025; Table 2). The
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percentage and absolute change in BH volume from
baseline to Year 3 also differed significantly between
dosage groups, increasing in the 22 µg group and
decreasing in the 44 µg group (percentage change: P =
0.002; absolute change: P = 0.017 for comparison of
doses). There was no significant difference in change in
T1 Gd+ lesion volume over time between dosage groups.
The proportion of patients who had a decrease in T2
lesion volume between baseline and Year 3 was signifi-
cantly greater in the 44 µg group (72.1%) than in the 22
µg group (56.9%; P = 0.047; Figure 1). A similar trend
was seen for the proportion of patients with a decrease
in BH volume (44 µg: 54.1%; 22 µg: 39.4%; P = 0.067;
Figure 1). Multivariate logistic regression showed that
treatment with sc IFN b-1a 44 µg predicted a decrease in
T2 lesion volume and BH lesion volume compared with
the 22 µg dose (Table 3).
Cognitive outcomes and MRI measures of disease
Of the patients for whom follow-up data were available
at Year 3, 11.8% (18/152) had impaired performance on
≥3 cognitive tests (i.e. were cognitively impaired). The
proportion of patients with cognitive impairment was
significantly lower in the 44 µg group than in the 22 µg
group (6.0% vs 18.8%, P = 0.015).
The proportion of patients with a decrease in T2 or
BH volume did not differ significantly between those
with or without cognitive impairment (P = 0.236 for T2
lesion volume; P = 0.892 for BH volume). No significant
effect of sc IFN b-1a dose was observed.
Patients with ≥2 impaired cognitive tests at baseline
were less likely to have decreased T2 lesion volume over
the course of the study compared with patients with <2
impaired tests (P = 0.034; Table 4). There were no other
differences in MRI outcomes over 3 years between
patients with <2 or ≥2 impaired tests at baseline.
Predictors of clinical, MRI and cognitive outcomes at
Year 3
Predictors of clinical, MRI and cognitive outcomes at
Year 3 were identified using multivariate logistic regres-
sion. T1 Gd+ lesion number at baseline was a predictor
of being disease-free at Year 3 (odds ratio [OR]: 0.29,
95% confidence interval [CI]: 0.08-0.95). Baseline EDSS
score (OR: 0.53, 95% CI: 0.33-0.86), baseline T2 lesion
volume (OR: 1.01, 95% CI: 1.00-1.01) and disease-free
status over 3 years (OR: 0.31, 95% CI: 0.00-0.84) pre-
dicted the development of new BH over 3 years. Base-
line T2 lesion volume (OR: 1.01, 95% CI: 1.00-1.01) and
new T2 lesions over 3 years (OR: 6.68, 95% CI: 2.09-
21.52) predicted the development of new Gd+ lesions.
Predictors for the presence or absence of new T2 lesions
over 3 years were disease duration (OR: 0.91, 95% CI:
0.84-0.98), and the presence of new Gd+ lesions over 3
years (OR: 4.18, 95% CI: 1.57-11.19).
Treatment with the 44 µg dose of sc IFN b-1a, and
higher verbal IQ score at baseline, predicted better cog-
nitive outcomes at Year 3 (Table 3). Higher baseline T2
lesion volume was predictive of cognitive impairment
(≥3 impaired tests) at Year 3 (Table 3).
Table 1 Change in MRI parameters from baseline to Year 3 (pooled treatment groups)
MRI Parameter
T2 lesions T1 Gd+ lesions T1 black holes
Lesion volume, mm3 Baseline Year 3 Baseline Year 3 Baseline Year 3
N 158 158 154 154 156 156
Mean (SD) 5990.1 (7111.6) 5345.9 (6755.3) 73.8 (252.1) 25.6 (125.5) 1263.1 (2430.6) 1185.4 (2520.7)
Median 3378.5 2825.0 0.0 0.0 436.3 341.9
Q1, Q3 1052.9, 7358.5 782.0, 6918.5 0.0, 0.0 0.0, 0.0 76.5, 1189.2 67.9, 1160.0
Absolute change, mm3
N 158 154 156
Mean (SD) −644.2 (3072.1) −48.2 (269.3)* −77.7 (1056.8)
Median −135.6 0.0 0.0
Q1, Q3 −719.8, 86.7 0.0, 0.0 −89.5, 73.4
Percentage change†
N 158 34 132
Mean (SD) −7.6 (34.1)c −60.5 (149.4)‡ 0.3 (67.8)
Median −7.3 −100.0 −4.7
Q1, Q3 −23.8, 4.0 −100.0, −100.0 −32.1, 19.5
Gd+, gadolinium-enhancing; IFN, interferon.
*P = 0.0034 vs baseline; Wilcoxon signed rank test.
†Percentage change was not calculated for patients with a lesion volume of 0 mm3 at baseline.
‡P < 0.0001 vs baseline; Wilcoxon signed rank test.
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Table 2 Change in MRI parameters from baseline to Year 3 by IFN b-1a dosage
MRI Parameter
T2 lesion volume T1 Gd+ lesion volume T1 black hole volume
IFN b-1a, 22 μg sc tiw IFN b-1a, 44 μg sc tiw IFN b-1a, 22 μg sc tiw IFN b-1a, 44 μg sc tiw IFN b-1a, 22 μg sc tiw IFN b-1a, 44 μg sc tiw
Absolute change, mm3
N 72 86 70 84 71 85
Mean (SD) −174.9 (1609.8) −1037.2 (3863.3) −23.5 (198.5) −68.8 (316.3) 64.5 (608.5) −196.5 (1311.9)
Median −81.6 −169.7 0.0 0.0 0.0 −25.3
Q1, Q3 −654.5, 126.8 −1133.3, 13.5 0.0, 0.0 0.0, 0.0 −40.3, 92.5 −209.4, 26.8
P value 0.092 0.472 0.017
Percentage change
N 72 86 15* 19* 59* 73*
Mean (SD) −4.5 (27.3) −10.2 (38.9) −54.2 (177.5) −65.4 (127.9) 10.3 (49.3) −7.8 (79.1)
Median −3.4 −12.1 −100.0 −100.0 1.5 −16.1
Q1, Q3 −14.5, 4.3 −30.6, 2.8 −100.0, −100.0 −100.0, −100.0 −10.6, 23.2 −50.5, 19.0
P value 0.025 0.495 0.002
Gd+, gadolinium-enhancing; IFN, interferon; sc, subcutaneously; tiw, three times weekly.
*Percentage change was not calculated for patients with a lesion volume of 0 mm3 at baseline.
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MRI, QoL and psychosocial outcomes
The proportion of patients with a clinically relevant
change in QoL (MSQoL-54 total score only) from base-
line to Year 3 was lower in patients who had a decrease
in T2 lesion volume over the same interval (12.4%) than
in those with stable/increased T2 lesion volume (29.4%;
P = 0.009). No difference was seen in the proportion of
patients with or without a decrease in BH volume. Ana-
lyses of fatigue, depressive symptoms and social func-
tioning showed that the proportion of patients with
clinically relevant changes in these outcomes did not
differ according to whether or not T2 or BH lesion
volume decreased over 3 years (data not shown).
Multivariate analyses confirmed that a decrease in T2
lesion volume was a significant predictor of stable
MSQoL-54 total score (OR: 0.4, 95% CI: 0.16-1.00).
Higher baseline FIS (OR: 1.04, 95% CI: 1.01-1.08) and
total MSQoL-54 (OR: 1.08, 95% CI: 1.03-1.12) scores
were predictive of clinically relevant changes in MSQoL-
54 scores from baseline to Year 3.
Discussion
The beneficial effects of sc IFN b-1a on MRI measures of
disease in patients with RRMS are well recognized. In this
observational study, such effects were seen in patients
being treated and assessed under normal clinical practice
conditions, strengthening our results. Here we demon-
strated significant effects of sc IFN b-1a on T2 and T1 Gd
+ lesion volumes over 3 years in a large cohort of patients
with mild physical disability (mean EDSS score: 2.0).
Furthermore, most patients remained free from new T1
Gd+, T2 and BH lesions over the course of the study. A
dose-dependent effect was seen in several MRI outcomes,
with the 44 µg dose having a more pronounced benefit
than the 22 µg dose. Treatment with the 44 µg dose of
IFN b-1a also predicted better cognitive outcomes at Year
3. T2 lesion volume was found to be associated with poor
cognitive and QoL outcomes.
Over the 3-year study, sc IFN b-1a treatment was
associated with a significant reduction in T1 Gd+ and
T2 lesion volumes, with a significant benefit of the 44
μg dose demonstrated for T2 lesion volume. These find-
ings are consistent with those of the pivotal PRISMS
study, in which sc IFN b-1a reduced T2 BOD and CUA
lesion number over 2 years of treatment, with a dose-
dependent effect on T2 lesion number and activity [4,7].
Our data confirm that sc IFN b-1a has beneficial effects
on MRI measures of disease in this cohort of mildly dis-
abled patients with RRMS. It is interesting that no dose
effect was observed for T1 Gd+ lesions. As Gd+ lesions
are new lesions, it is possible that the lower 22 μg dose
of IFN b-1a is able to inhibit initial inflammatory pro-
cesses in these patients in the early stages of disease.
Indeed, an effect of sc IFN b-1a on active MRI lesions
was reported at Month 2 in the PRISMS study, during
which patients received lower doses of IFN b-1a during
titration up to the 44 µg tiw dose [4]. The dose effect
may, however, become evident when assessing longer-
term MRI measures such as T2 lesion volume, which
capture both old and new lesions. It is possible that
newer lesions are more susceptible to the effects of sc
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Figure 1 Proportion of patients with a decrease in T2 lesion
volume or T1 black hole (BH) volume from baseline to Year 3,
by interferon (IFN) b-1a dose group. sc, subcutaneously; tiw,
three times weekly.
Table 3 Predictors of cognitive impairment at Year 3,
defined as impaired performance on ≥3 cognitive tests
(multivariate logistic regression)
Odds ratio 95% CI
Stable/increased T2 lesion volume over 3 years
Treatment with sc IFN b-1a 44 µg tiw 0.45 0.23-0.91
Baseline BH lesion volume 1.01 1.00-1.01
Number of new T2 lesions 1.13 1.02-1.26
Stable/increased BH volume over 3 years
Treatment with sc IFN b-1a 44 µg tiw 0.46 0.23-0.92
ESS score at baseline 0.82 0.69-0.98
Presence of new BH over 3 years 3.21 1.52-6.75
Three or more impaired cognitive tests at Year 3
Baseline T2 lesion volume 1.01 1.00-1.01
Verbal IQ* 0.92 0.87-0.98
IFN b-1a, 44 μg sc tiw 0.31 0.10-0.98
CI, confidence interval; IFN, interferon; IQ, intelligence quotient; sc,
subcutaneously; tiw, three times weekly.
*Higher score denotes superior outcome.
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IFN b-1a than more established, chronic and inactive
lesions.
The presence of BH indicates areas of axonal loss (neu-
rodegeneration). Although we did not find a significant
effect on BH lesion volume from baseline to Year 3 in
the whole cohort, a significant difference between the
two treatment groups was seen regarding the change in
BH volume: BH volume increased in the 22 µg group,
but decreased in the 44 µg group over the 3-year study.
Whether IFN b-1a is neuroprotective is still a subject of
some debate; however, our findings may suggest that the
44 µg dose of sc IFN b-1a could have neuroprotective
effects. This is a particularly interesting finding as BH
were not measured in earlier studies of DMDs, and
hence how BH are associated with long-term treatment-
related clinical outcomes is not known [8].
At Year 3, only 11.8% of patients had impaired perfor-
mance on ≥3 cognitive tests. This is slightly lower than
the proportion reported in the parent COGIMUS study
[17], which may reflect differences between patients who
underwent MRI scans and those who did not. Treatment
with the 44 µg dose of IFN b-1a was associated with bet-
ter cognitive outcomes, whereas higher T2 lesion load
predicted cognitive decline. An association between T2
lesions and cognitive impairment has been reported pre-
viously [16,25-28]. As we saw a clear, dose-related effect
of treatment on MRI measures and an association
between T2 lesions and cognition, it is interesting to
speculate on how the effect on different MRI lesion types
may translate into cognitive benefits. Loss of axons (BH)
could result in loss of neuronal connectivity, whereas T2
lesions might indicate reduced efficiency of neurotrans-
mission owing to myelin degradation. Mapping the distri-
bution of MS lesions and assessment of those in regions
known to govern cognitive processes could provide
further insights into how the effects of IFN b-1a treat-
ment on MRI parameters are associated with cognitive
benefits. Metabolic studies may also further explain the
relation between treatment effects on MRI parameters
and cognitive outcomes. In one study using positron
emission tomography, the cortical rate of glucose meta-
bolism was shown to be reduced significantly in patients
with MS compared with healthy controls, and was inver-
sely correlated with T2 BOD and cognitive performance
[29]. White matter lesions could denervate cortical areas
and be responsible for the observed reduction in cortical
glucose metabolism resulting in clinical symptoms.
Decreased T2 lesion volume also predicted better QoL
scores. Associations between MRI parameters (white
matter lesion loads and brain atrophy) and QoL out-
comes have been described in a cross-sectional analysis
of patients with MS [30]. Here, we have assessed longitu-
dinal treatment effects on QoL and MRI disease mea-
sures. Together, our and previous observations suggest
that treatment-related reductions in MS lesion burden
may have a positive effect on patients’ daily lives. It is
also possible that starting treatment may have positive
psychological effects due to the patient’s expectation that
their treatment will reduce relapses and protect against
worsening disability and cognitive impairment that lead
to improved QoL. No associations were found between
MRI measures and fatigue, depressive symptoms or social
functioning in our analysis. However, higher fatigue at
baseline did predict worsening QoL. These findings
demonstrate the complexity of MS and the importance of
measuring both pathological and symptomatic para-
meters to understand fully the impact of MS on the
patient.
The limitations of this analysis should be considered.
This was a post hoc analysis of data from an observational
study, and there was no untreated comparator group;
treatment effects should therefore be interpreted with cau-
tion. Consequently, differences observed between the
lower and higher doses of sc IFN b-1a may have been
affected by selection bias, although treatment groups were
balanced with regard to main demographic variables. In
addition, MRI data at Year 3 were missing for approxi-
mately half of the patients with baseline MRI data.
Furthermore, among those patients from whom MRI data
were collected over 3 years’ follow-up, data for some para-
meters were missing. Despite this, we collected MRI and
cognition data for >300 patients at baseline and for >150
patients at Year 3, making this a valuable data set, particu-
larly considering the mild disability and short disease
duration in this cohort. Notably, there were some impor-
tant differences between patients with and without 3-year
MRI data, including the proportion who had cognitive
impairment, and in EDSS scores. This finding may have
influenced the other results reported here and highlights
the difficulties that can be encountered with data collec-
tion in longitudinal studies. Concerning MRI parameters,
we did not assess cortical pathology (inflammatory lesions
and atrophy), which has recently been shown to contribute
considerably to neuropsychological symptoms in MS
Table 4 Association between changes in T2 lesion volume over 3 years and baseline cognitive impairment
≥2 impaired cognitive tests at baseline
No (n = 114) Yes (n = 44) P-value
Stability or increase of T2 lesion volume, n (%) Yes 34 (29.8) 21 (47.7) 0.034
No 80 (70.2) 23 (52.3)
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[31,32]. As the importance of cortical pathology in MS,
particularly with respect to cognitive outcomes, emerged
after the start of the COGIMUS study it was not possible
to include such assessments in this analysis. In addition, it
should be noted that Gd+ lesions can only be detected for
a time period of around 1 month at most, so it is possible
that some of these lesions may not have been counted due
to the scans being performed annually; however, this inter-
val was dictated by routine practice due to the observa-
tional nature of the study. Finally, due to low patient
numbers, it was necessary to define cognitive impairment
as impaired performance on ≥2 cognitive tests to investi-
gate associations between MRI parameters and cognitive
status, whereas the definition in the parent COGIMUS
study required impairment on ≥3 tests.
Conclusions
These findings demonstrate that sc IFN b-1a has a bene-
ficial effect on MRI measures of disease in a population
of patients with early RRMS and mild physical disability
in a normal clinical setting. A dose effect was seen on
MRI outcomes, notably on BH, an indicator of neurode-
generation, and was greater with the 44 µg than with the
22 µg dose of sc IFN b-1a. T2 lesion load and treatment
with the higher dose of sc IFN b-1a predicted preserved
cognitive function over the 3-year study. These results
confirm the efficacy of sc IFN b-1a in RRMS and suggest
that effects on MRI measures may underlie potential cog-
nitive and QoL benefits of this treatment.
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